Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Multicentre Clinical Study Of ZD1839 (Iressa™) In Combination With Capecitabine (Xeloda™) In Subjects With Advanced Colorectal Carcinoma After Failure Of First-Line Chemotherapy

NCT00242788 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00242788
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00242788 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Multicentre Clinical Study Of ZD1839 (Iressa™) In Combination With Capecitabine (Xeloda™) In Subjects With Advanced Colorectal Carcinoma After Failure Of First-Line Chemotherapy
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Completed
Start date
February 29, 2004
Completion date
November 30, 2005
Enrollment
40
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer